Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast, Advisory

ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020 American Society of Clinical Psychopharmacology (ASCP) Virtual Annual Meeting on May 29-30, 2020.

"Our research presentations at ASCP underscore the potential clinical utility of pimavanserin in serious CNS disorders," said Serge Stankovic, M.D., M.S.P.H., ACADIA's President. "We look forward to sharing data from our pivotal studies in negative symptoms of schizophrenia and major depressive disorder where pimavanserin has demonstrated the potential to be an important treatment option for patients, as well as new long-term safety and tolerability data of NUPLAZID® in Parkinson's disease psychosis."

ASCP Accepted Scientific Presentations include:

Negative Symptoms of Schizophrenia


Parkinson's Disease Psychosis

About Pimavanserin

Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in psychosis, schizophrenia, depression and other neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. ACADIA is evaluating pimavanserin in an extensive clinical development program across multiple indications with significant unmet need including dementia-related psychosis, adjunctive major depressive disorder, and the negative symptoms of schizophrenia. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID®. NUPLAZID is not approved for dementia-related psychosis, schizophrenia, major depressive disorder or depression in patients with Parkinson's disease.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to: the potential benefits of pimavanserin as adjunctive treatment for major depressive disorder, the negative symptoms of schizophrenia or other central nervous system disorders as well as the potential results of clinical trials of pimavanserin in other indications. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2019 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Important Safety Information and Indication for NUPLAZID (pimavanserin)


Indication: NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Dosage and Administration: Recommended dose: 34 mg capsule taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please see the full Prescribing Information including Boxed WARNING for NUPLAZID.

These press releases may also interest you

at 10:45
Spectroscopy® and LCGCtm , two MJH Life Sciencestm publications, are proud to announce that Lydia Neguse, a junior at California Academy of Mathematics and Science School in Carson, won the 2020 Most Outstanding Female in Chemistry or Chemical...

at 10:45
The "Global Sanitizer Market - Analysis by Product Type (Gel, Liquid, Others), by End User, by Region, by Country (2020 Edition): Market Insights, COVID-19 Implications, Competition and Forecast (2020-2025)" report has been added to...

at 10:45
It's probably safe to say that many people have experienced back and neck pain from spinal abnormalities and degeneration. Fortunately, an inventor from Kalispell, Mont., has found a way to enable users to apply tension to alleviate discomfort from...

at 10:42
TopDevz, one of America's fastest-growing software consulting firm, announced today the successful delivery of a new custom mobile application for one of the US' largest insurance broker....

at 10:40
Valeo Pharma Inc.  ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company,  announced today that it has received a Notice of Compliance from Health Canada authorizing the transfer of the AmetopTM commercial rights to Valeo.  Valeo...

at 10:30
Future Market Insights' recent report on the protein a-resins market concludes that the market is anticipated to witness robust growth across the upcoming decade's forecast period. Growing investments in synthetic biology is accelerating adoption of...

News published on 21 may 2020 at 09:05 and distributed by: